Further investment in Phasefocus Holdings Limited

21 August 2023

Braveheart Investment Group Plc

("Braveheart", the "Company" or the "Group")

Further investment in Phasefocus Holdings Limited

Braveheart Investment Group (AIM: BRH), is pleased to announce a further investment into Phasefocus Holdings Limited ("Phasefocus"). The Company has purchased 18,750 new ordinary shares of one pence each in Phasefocus at a price of £8 per share for a total consideration of £150,000, taking Braveheart's total interest to 48.3 per cent. of the issued share capital of Phasefocus.

Phasefocus' imaging and analysis system, Livecyte®, uses a novel patented method for high fidelity quantitative imaging and microscopy; this is known in the scientific literature as 'ptychography'.

As announced on 31 May 2023, Phasefocus has gained substantial momentum during the year and its work, in particular with distributors in Japan, China and the USA, has built a strong pipeline of business opportunities. Phasefocus has received a number of orders for its Livecyte® system, which are scheduled to be delivered before the end of 2023.

On 14 August 2023, Phasefocus announced the launch of its revolutionary new T-Cell Killing Assay for the Livecyte® cell imaging platform https://www.phasefocus.com/about/news-events/news/t-cell-assay-announcement. The new assay quantifies interactions between immune cells and cancer cells, addressing a major unmet need for researchers developing the latest novel cancer therapies.  In the assay, the characteristics of T cell interactions in the period immediately preceding target cell death, can be measured independently from cytotoxicity. Livecyte's T-Cell Killing Assay offers unparalleled insights at the single-cell level, empowering researchers to unlock new frontiers in cancer therapy development and evaluation.

This investment by Braveheart will provide Phasefocus with the working capital to market its new T-Cell Killing Assay and build Livecyte® stock, in preparation for further anticipated orders, and follows a £134,000 investment by the Company into Phasefocus in January 2023.

In the year ended 31 December 2022, Phasefocus incurred a loss before taxation of £990,854. The book value of Braveheart's investment in Phasefocus at 31 March 2023 (prior to this investment) was £2.5 million.

Trevor Brown, Chief Executive Officer of Braveheart, commented:  

"Phasefocus is making impressive progress on sales and innovation making the decision to increase our investment an easy one. The potential realization value of our interest also continues to grow, reflecting these advances."

For further information: